Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study

INTRODUCTION: The efficacy and safety of recombinant factor VIII Fc fusion protein (rFVIIIFc) as an extended half‐life treatment for severe haemophilia A were demonstrated in the Phase 3 A‐LONG and Kids A‐LONG studies. Eligible subjects who completed A‐LONG and Kids A‐LONG could enrol in ASPIRE (NCT...

Descripción completa

Detalles Bibliográficos
Autores principales: Nolan, Beatrice, Mahlangu, Johnny, Pabinger, Ingrid, Young, Guy, Konkle, Barbara A., Barnes, Chris, Nogami, Keiji, Santagostino, Elena, Pasi, K. John, Khoo, Liane, Winding, Bent, Yuan, Huixing, Fruebis, Joachim, Rudin, Dan, Oldenburg, Johannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384031/
https://www.ncbi.nlm.nih.gov/pubmed/32227570
http://dx.doi.org/10.1111/hae.13953

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384031/
https://www.ncbi.nlm.nih.gov/pubmed/32227570
http://dx.doi.org/10.1111/hae.13953

Ejemplares similares